{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,11]],"date-time":"2025-12-11T16:43:33Z","timestamp":1765471413320,"version":"3.48.0"},"reference-count":23,"publisher":"Mark Allen Group","issue":"S11a","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Wound Care"],"published-print":{"date-parts":[[2025,11,1]]},"abstract":"<jats:sec>\n                    <jats:title>Objective:<\/jats:title>\n                    <jats:p>The purpose of this retrospective case series is to describe real-world clinical experience with DermaBind TL or FM, (HealthTech Wound Care, US), a dehydrated full-thickness placental membrane intended for homologous use as a protective wound covering in wounds of various aetiologies that failed to heal with standard of care (SoC).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Method:<\/jats:title>\n                    <jats:p>This retrospective observational, uncontrolled case series collected data from healthcare providers in the US. Eligible cases were patients, \u226518 years of age, with hard-to-heal wounds who received DermaBind TL or FM after having completed a minimum of four weeks of SoC without evidence of wound improvement. Data collected included patient demographics, wound characteristics and wound size.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      The cases of 27 patients encompassing 36 wounds were included. The average age of patients included was 72.4 years (range: 37\u2013101 years). The majority of wounds were pressure ulcers (63.9%), followed by diabetic foot ulcers (19.4%) and venous leg ulcers (8.3%). Wound onset was, on average, 29 weeks prior to the first graft application with the placental membrane, and the average wound size was 34cm\n                      <jats:sup>2<\/jats:sup>\n                      . Graft applications occurred weekly, with an average duration of treatment of 6.7 weeks. The observed average percentage surface area reduction across the 36 wounds was 69.1% (range: \u201317.6\u2013100%). No adverse events were reported by the provider across all patient cases.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>These observations describe the clinical use of DermaBind as a wound covering material consistent with its homologous natural protective role. Larger, prospective studies are warranted to further investigate its clinical use. The authors would like to stress that this non-randomised, retrospective uncontrolled case series was used to describe findings, such as number of grafts applied, observed percentage of surface area reduction and graft wasted, and not to demonstrate efficacy.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.12968\/jowc.2025.0448","type":"journal-article","created":{"date-parts":[[2025,10,16]],"date-time":"2025-10-16T16:18:16Z","timestamp":1760631496000},"page":"S5-S14","source":"Crossref","is-referenced-by-count":0,"title":["Clinical use of DermaBind TL\/FM as a wound covering for hard-to-heal wounds of various aetiologies: a case series"],"prefix":"10.12968","volume":"34","author":[{"given":"Jason","family":"Mendivil","sequence":"first","affiliation":[{"name":"PULSE Amputation Prevention Centers, US"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abby E","family":"McMahon","sequence":"additional","affiliation":[{"name":"EvoHealth, US"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Oludayo Toby","family":"Ojelade","sequence":"additional","affiliation":[{"name":"EvoHealth, US"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kelly","family":"Hobson","sequence":"additional","affiliation":[{"name":"Reliable Visiting Services, US"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Melissa","family":"Marballie","sequence":"additional","affiliation":[{"name":"The Family Wound Care, US"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sandry","family":"Alvarez","sequence":"additional","affiliation":[{"name":"Maxcure Medical Center, US"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vivian","family":"Adu-Aboagye","sequence":"additional","affiliation":[{"name":"BWell Medical and Wellness Center, US"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Georgia","family":"Chiamba","sequence":"additional","affiliation":[{"name":"Aptitude Health, US"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Donovan","family":"Gowdie","sequence":"additional","affiliation":[{"name":"The Foot and Ankle Treatment Center, US"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Willie E","family":"Landrum II","sequence":"additional","affiliation":[{"name":"Willie E Landrum II, MD, PC Internal Medicine, US"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ahlam","family":"Alzindani","sequence":"additional","affiliation":[{"name":"Visiting Doctors Solutions, US"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Habeeb","family":"Yazdani","sequence":"additional","affiliation":[{"name":"Visiting Doctors Solutions, US"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gabriel","family":"Petty","sequence":"additional","affiliation":[{"name":"Synova Health, US"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marie-Chantale","family":"Simard","sequence":"additional","affiliation":[{"name":"Silver Raven Advisory LLC, US"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Douglas","family":"Schmid","sequence":"additional","affiliation":[{"name":"HealthTech Wound Care, US"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jessica","family":"Meadors","sequence":"additional","affiliation":[{"name":"HealthTech Wound Care, US"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"5130","reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1063\/1.5026773"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1152\/physrev.00067.2017"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1038\/s41572-022-00377-3"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.3390\/bioengineering10070829"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.12968\/jowc.2024.0141"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1101\/cshperspect.a041243"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.3390\/cells10030655"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-024-06262-w"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1089\/wound.2023.0150"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1080\/13696998.2023.2232256"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.12968\/bjon.2004.13.Sup3.15546"},{"issue":"4","key":"B12","first-page":"662","volume":"13","author":"Lei J","year":"2019","journal-title":"Health Sci J"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.2217\/nnm.13.50"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.3390\/jfb14100531"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1111\/iwj.12097"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1186\/2045-824X-6-10"},{"issue":"8","key":"B17","first-page":"289","volume":"12","author":"Gleason J","year":"2022","journal-title":"J Biotechnol Biomater"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1097\/GOX.0000000000001095"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijscr.2019.12.033"},{"key":"B20","unstructured":"National Archives. Code of Federal Regulations. CFR part 1271\u2014Human cells, tissues, and cellular and tissue-based products. https:\/\/tinyurl.com\/3yf28239 (accessed 13 October 2025)"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1097\/WON.0b013e3181d73aab"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.12968\/jowc.2019.28.Sup3a.S1"},{"key":"B23","unstructured":"Centers for Medicare and Medicaid Services. Local coverage determination: skin substitute grafts\/cellular and tissue-based products for the treatment of diabetic foot ulcers and venous leg ulcers. 2024. https:\/\/tinyurl.com\/54mvbfvf (accessed 6 October 2025)"}],"container-title":["Journal of Wound Care"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.magonlinelibrary.com\/doi\/pdf\/10.12968\/jowc.2025.0448","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,11]],"date-time":"2025-12-11T16:40:09Z","timestamp":1765471209000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.magonlinelibrary.com\/doi\/10.12968\/jowc.2025.0448"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,1]]},"references-count":23,"journal-issue":{"issue":"S11a","published-print":{"date-parts":[[2025,11,1]]}},"alternative-id":["10.12968\/jowc.2025.0448"],"URL":"https:\/\/doi.org\/10.12968\/jowc.2025.0448","relation":{},"ISSN":["0969-0700","2052-2916"],"issn-type":[{"type":"print","value":"0969-0700"},{"type":"electronic","value":"2052-2916"}],"subject":[],"published":{"date-parts":[[2025,11,1]]}}}